Publisher John Wiley & Sons, Inc. has announced an extended publishing partnership with the Federation of European Biochemical Societies (FEBS) with the move of Molecular Oncology from January 2017 to join the other three FEBS publications published by Wiley - The FEBS Journal, FEBS Letters, and FEBS Open Bio at FEBS Press. FEBS has become one of Europe's largest organisations in the molecular life sciences, providing a voice to a large part of the academic research and teaching community in Europe.
With Molecular Oncology’s transition to Wiley, all four journals will be discoverable on the new FEBS Press platform on Wiley Online Library. FEBS Press will ensure the journals continue to serve and support the research community and remain the journals of choice for authors and readers.
Molecular Oncology publishes high-impact discoveries and technical advances in basic, clinical and discovery-driven translational cancer research, and has an Impact Factor of 5.367. When Molecular Oncology joins Wiley in January 2017 it will also make the change to become a fully Open Access journal.
Brought to you by Scope e-Knowledge Center, a world-leading provider of metadata services, abstraction, indexing, entity extraction and knowledge organisation models (Taxonomies, Thesauri and Ontologies).
